Ascelia Pharma

Ascelia Pharma Stock-Based Compensation

The Stock-Based Compensation (SBC) of Ascelia Pharma (ACE.ST) as of Nov 20, 2026 is 4.16 M SEK. In the previous year, Stock-Based Compensation (SBC) was 4.34 M SEK — a change of -4.06% (lower).

Stock-Based Compensation

4.16 MSEK

YoY

-4.06%

Last updated:

Stock-Based Compensation (SBC) of Ascelia Pharma is 2025 4.16 M SEK. Stock-Based Compensation (SBC) of Ascelia Pharma was 2024 4.34 M SEK. It decreases by -4.06% lower compared to the previous year.

The Ascelia Pharma Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2018
2.26 M SEK
Jan 1, 2019
3,297.00 SEK
Jan 1, 2020
7.87 M SEK
Jan 1, 2021
5.92 M SEK
Jan 1, 2022
1.63 M SEK
Jan 1, 2023
2.93 M SEK
Jan 1, 2024
4.34 M SEK
Jan 1, 2025
4.16 M SEK
The Ascelia Pharma Stock-Based Compensation history
YEARStock-Based CompensationYoY
4.16 MSEK-4.06%
4.34 MSEK+48.07%
2.93 MSEK+80.15%
1.63 MSEK-72.51%
5.92 MSEK-24.82%
7.87 MSEK+238,692.84%
3,297.00SEK-99.85%
2.26 MSEK-49.30%
4.45 MSEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ascelia Pharma Stock analysis

What does Ascelia Pharma do? Ascelia Pharma AB develops pharmaceutical products for cancer treatment, focusing on underappreciated drug candidates. The company's pipeline includes Mangoral, a medical imaging drug for liver MRI in patients with impaired kidneys, which has completed phase II clinical trials, and Oncoral, a tablet formulation of irinotecan for gastric cancer treatment, currently in phase I development. Ascelia generates revenue through the development and potential commercialization of these drug candidates, targeting oncology markets with unmet medical needs. The firm identifies and acquires derisked investigational drug candidates, aiming to make them available to cancer patients. Mangoral addresses liver metastases detection in impaired kidney patients, while Oncoral targets gastric cancer treatment. Ascelia's business model relies on advancing these candidates through clinical trials to secure partnerships or regulatory approvals for market entry. Ascelia Pharma AB is headquartered in Malmö, Skåne, and employs 24 full-time staff. The company went public via IPO on March 13, 2019. Its revenue model centers on progressing its pipeline to attract potential partners or buyers for its drug candidates, with no mention of current sales or external funding sources beyond the IPO. Ascelia Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ascelia Pharma stock

Stock-Based Compensation (SBC) of Ascelia Pharma is 4.16 M SEK in 2025.

Stock-Based Compensation (SBC) of Ascelia Pharma changed from 4.34 M SEK to 4.16 M SEK, representing a -4.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Ascelia Pharma since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Ascelia Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Ascelia Pharma

All Key Metrics — Ascelia Pharma